Antiviral screen of SARS-CoV-2 ASOs in H1437 cells.

(A) SARS-CoV-2 bioassay showing infectivity and cell viability with the most active 26 SARS-CoV-2 Gapmers at 10 μM against WA1 strain in H1437 cells. (B) SARS-CoV-2 bioassay showing infectivity and cell viability with the most active 3 SARS-CoV-2 Gapmers at 10, 3, 1, and 0.3 μM treatments against WA1 strain in H1437 cells. (C) Representative images of H1437 cells after 10 μM indicated ASOs treatment. (D) SARS-CoV-2 bioassay showing infectivity and cell viability with the most active SARS-CoV-2 Gapmers and corresponding inactive controls at 3 μM against WA1 strain in H1437 cells. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl). (E) SARS-CoV-2 bioassay showing infectivity and cell viability with the most active SARS-CoV-2 Gapmers and corresponding inactive controls at 3 μM against B.1.1.7 strain in H1437 cells. P values were calculated using two tailed unpaired t test by comparing to control (Ctrl). (F) SARS-CoV-2 bioassay showing infectivity and cell viability with the most active SARS-CoV-2 uniform MOE ASOs and corresponding inactive controls at 3 μM against WA1 strain in H1437 cells.